Skip to main content
Premium Trial:

Request an Annual Quote

Another Company, Another Childhood


Frank Lee swears it’s not a midlife crisis. Lee, 49, left his CTO post at Millennium Pharmaceuticals to become president and CEO of EngeneOS, a startup with fewer than 10 employees incubated by NewcoGen. “I was interested in going back to an earlier stage company,” says Lee, who remembers well Millennium’s nascent phase. Another attraction was the added responsibility: “I wanted to move from the pure science and technology role.”

The switch to CEO and president should accomplish that. EngeneOS hopes to develop a business around disciplines as varied as biology, genomics, physics, engineering, and electronics. The goal is to engineer electronic devices using peptides or nucleic acids as scaffolds. Potential applications exist in pharmaceuticals, diagnostics, and chemical synthesis.

Lee expects the company to grow through internal expansion of its science and business teams as well as through strategic partnerships. Lee, whose background is in molecular biology, considers his move to EngeneOS an “opportunity to do something fun and different.”

— Meredith Salisbury


The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.